Ticker
ABMD

Price
381.02
Stock movement up
+- (%)
Company name
ABIOMED Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Medical Devices
Market cap
17.18B
Ent value
17.16B
Price/Sales
16.00
Price/Book
11.16
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
64.40
Forward P/E
60.77
PEG
-
EPS growth
-
1 year return
8.18%
3 year return
30.28%
5 year return
14.86%
10 year return
39.53%
Last updated: 2023-02-06

DIVIDENDS

ABMD does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E64.40
Price to OCF68.45
Price to FCF112.19
Price to EBITDA46.29
EV to EBITDA46.22

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales16.00
Price to Book11.16
EV to Sales15.97

FINANCIALS

Per share

Loading...
Per share data
Current share count45.09M
EPS (TTM)5.84
FCF per share (TTM)3.35

Income statement

Loading...
Income statement data
Revenue (TTM)1.07B
Gross profit (TTM)873.51M
Operating income (TTM)253.61M
Net income (TTM)266.76M
EPS (TTM)5.84
EPS (1y forward)6.27

Margins

Loading...
Margins data
Gross margin (TTM)81.32%
Operating margin (TTM)23.61%
Profit margin (TTM)24.84%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash182.34M
Net receivables94.47M
Total current assets1.06B
Goodwill72.96M
Intangible assets50.13M
Property, plant and equipment0.00
Total assets1.70B
Accounts payable35.07M
Short/Current long term debt0.00
Total current liabilities134.06M
Total liabilities156.76M
Shareholder's equity1.54B
Net tangible assets1.43B

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)250.98M
Capital expenditures (TTM)33.76M
Free cash flow (TTM)153.14M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity17.32%
Return on Assets15.72%
Return on Invested Capital17.32%
Cash Return on Invested Capital9.95%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open381.02
Daily high381.02
Daily low381.02
Daily Volume0K
All-time high449.75
1y analyst estimate363.00
Beta1.40
EPS (TTM)5.84
Dividend per share-
Ex-div date-
Next earnings date26 Apr 2023

Downside potential

Loading...
Downside potential data
ABMDS&P500
Current price drop from All-time high-15.28%-19.84%
Highest price drop-94.31%-56.47%
Date of highest drop9 Oct 20029 Mar 2009
Avg drop from high-47.58%-11.49%
Avg time to new high46 days13 days
Max time to new high3756 days1805 days
COMPANY DETAILS
ABMD (ABIOMED Inc) company logo
Marketcap
17.18B
Marketcap category
Large-cap
Description
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts. As of December 22, 2022, Abiomed, Inc. operates as a subsidiary of Johnson & Johnson.
Employees
2003
Investor relations
-
SEC filings
CEO
Michael R. Minogue
Country
USA
City
Danvers
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Johnson & Johnson Inc. closed its acquisition of Danvers medical device maker Abiomed Inc. on Thursday. The deal weighed in at $16.6 billion, making it easily one of the largest acquisitions of the ye...
December 22, 2022
Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.
December 22, 2022
DANVERS, Mass., December 21, 2022--Abiomed Announces First Patients Enrolled in FDA Pivotal Trial for Impella ECP, World’s Smallest Heart Pump
December 21, 2022
S&P MidCap 400 constituent Steel Dynamics Inc. (NASD:STLD) will replace Abiomed Inc. (NASD:ABMD) in the S&P 500 and Super Micro Computer Inc. (NASD:SMCI) will replace Steel Dynamics in the S&P MidCap ...
December 19, 2022
In this article, we discuss the 10 best performing stocks in November. If you want to read about some more best performing stocks in November, go directly to 5 Best Performing Stocks in November. Afte...
December 13, 2022
Johnson & Johnson (NYSE: JNJ) is in the midst of a transition. One way the business can accelerate its plans for growth is via acquisitions, and Johnson & Johnson has been busy on that front of late....
December 8, 2022
DANVERS, Mass., December 05, 2022--Abiomed announces the first three patients in the world have been treated with Impella RP Flex with SmartAssist.
December 5, 2022
Abiomed (ABMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
December 1, 2022
Most S&P 500 investors got a little gain this month. But investors willing to look off the beaten path found huge gains.
November 30, 2022
Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.
November 22, 2022
Next page